Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2025)

Historic Research & Development for Connect Biopharma Holdings (CNTB) over the last 2 years, with Q3 2025 value amounting to $11.1 million.

  • Connect Biopharma Holdings' Research & Development rose 2332.11% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year change of. This contributed to the annual value of $29.3 million for FY2024, which is 4480.21% down from last year.
  • Per Connect Biopharma Holdings' latest filing, its Research & Development stood at $11.1 million for Q3 2025, which was up 2332.11% from $8.8 million recorded in Q2 2025.
  • In the past 5 years, Connect Biopharma Holdings' Research & Development registered a high of $11.1 million during Q3 2025, and its lowest value of $5.3 million during Q2 2024.